Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and verbal memory in schizophrenia and bipolar disorder. by Houenou, Josselin et al.
Cytomegalovirus seropositivity and serointensity are
associated with hippocampal volume and verbal memory
in schizophrenia and bipolar disorder.
Josselin Houenou, Marc-Antoine D’Albis, Claire Daban, Nora Hamdani,
Marine Delavest, Jean-Pierre Le´pine, Franc¸ois-Eric Vederine, S. Carde,
Mohamed Lajnef, Christel Cabon, et al.
To cite this version:
Josselin Houenou, Marc-Antoine D’Albis, Claire Daban, Nora Hamdani, Marine Delavest, et al..
Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and
verbal memory in schizophrenia and bipolar disorder.. Progress in Neuro-Psychopharmacology
and Biological Psychiatry, Elsevier, 2013, 48C, pp.142-148. <10.1016/j.pnpbp.2013.09.003>.
<inserm-00877593>
HAL Id: inserm-00877593
http://www.hal.inserm.fr/inserm-00877593
Submitted on 28 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Cytomegalovirus seropositivity and serointensity are associated with hippocampal volume and 
verbal memory in schizophrenia and bipolar disorder  
 
 
Houenou Ja,b,c,d*, d'Albis MAa,b,c,e, Daban Ca,b,c, Hamdani Na,b,c, Delavest Mb,f, Lepine JPb,f, Vederine 
FEa,c, Carde Sa,c, Lajnef Ma,b, Cabon C g, Dickerson Fh, Yolken RHh, Tamouza R.i, Poupon C. d, Leboyer 
Ma,b,c,e 
 
a) Inserm, U955, Equipe 15 « Psychiatrie Génétique », Créteil, F-94000, France 
b) Fondation Fondamental, Créteil, F-94010, France 
c) AP-HP, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie, Créteil, F-94000, France  
d) Neurospin, CEA Saclay, Gif-Sur-Yvette, France 
e) Université Paris Est, Faculté de médecine, Créteil, F-94000, France 
f) AP-HP, Service de Psychiatrie, Hôpital Lariboisiere Fernand Widal, Inserm U 705 Cnrs UMR 8206, 
Paris Diderot University, F-75010, Paris, France 
g) Plateforme de ressources biologiques, GH Henri Mondor, Créteil, F-94000, France 
h) Stanley Research Program, Sheppard Pratt, Baltimore, MD, USA 
i) AP-HP, Laboratoire Jean Dausset d'Immunologie et d'Histocompatibilité & INSERM, UMRS 940, 
Hôpital Saint Louis, Univ Paris Diderot, Paris, F-75010, France 
 
*Corresponding author:  
Dr Josselin Houenou, AP-HP, Groupe Henri Mondor - Albert Chenevier, Pôle de psychiatrie, 40 rue 
de Mesly, Créteil, 94000, France.  
Tel : +33 1 49 81 30 51 
Fax : +33 1 49 81 30 59 
Email : josselin.houenou@inserm.fr 
 
ABSTRACT 
Introduction: Cytomegalovirus (CMV) is a member of the herpesviridae family that has a limbic 
and temporal gray matter tropism. It is usually latent in humans but has been associated with 
schizophrenia, bipolar disorder and cognitive deficits in some populations. Hippocampal decreased 
volume and dysfunction play a critical role in these cognitive deficits. We hypothesized that CMV 
seropositivity and serointensity would be associated with hippocampal volume and cognitive 
functioning in patients with schizophrenia or bipolar disorder.  
 
Methods: 102 healthy controls, 118 patients with bipolar disorder and 69 patients with 
schizophrenia performed the California Verbal Learning Test (CVLT) and had blood samples drawn 
to assess CMV IgG levels. A subgroup of 52 healthy controls, 31 patients with bipolar disorder and 
27 patients with schizophrenia underwent T1 MRI for hippocampal volumetry. We analyzed the 
association between CMV serointensity and seropositivity with hippocampal volume. We also 
explored the correlation between CMV serointensitiy and seropositivity and CVLT scores. 
 
Results: In both patients groups but not in controls, higher CMV serointensity was significantly 
associated with smaller right hippocampal volume. Further, in the group of patients with 
schizophrenia but not bipolar disorder, CMV serointensity was negatively correlated with CVLT 
scores.  
 
Conclusion: CMV IgG titers are associated with decreased hippocampal volume and poorer 
episodic verbal memory in patients with schizophrenia or bipolar disorder. The mechanism of this 
association warrants further exploration. 
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1. INTRODUCTION1 
 
Human cytomegalovirus (CMV) is a member of the herpesviridae family. Herpes viruses are large 
enveloped DNA viruses. CMV is being transmitted by intimate contact with infected excretions 
such as saliva, urine, cervical and vaginal excretions, semen, breast milk, or blood. Risk factors for 
CMV exposure are breast-feeding, crowding, increased contact with infants and toddlers, poor 
hygiene, multiple sex partners and promiscuity (Gaytant et al., 2002). The prevalence of CMV 
infection in adults is at least 60% in developed countries and 80% in developing countries (Gaytant 
et al., 2002; Staras et al., 2006). CMV is neurotropic and asymptomatic in humans, except in 
certain conditions (congenital infection, immunodepression) (Bristow et al., 2011). In 
immunocompetent subjects, CMV infection is considered to be latent, asymptomatic and non-
pathogenic. Some authors have nevertheless suggested a neuronal, or at least gray-matter, 
tropism of CMV during this latent phase (Perron et al., 2009; Shinmura et al., 1997; Tsutsui, 2009; 
Tsutsui et al., 2005). CMV has an affinity for the limbic structures (Yolken and Torrey, 2008) and 
for the temporal lobe (Hoffmann et al., 2010) as described for other herpesviruses. Animal models 
suggest that CMV may persistently infect neuronal cells, with a specific tropism for the 
hippocampus (Arai et al., 2003; Shinmura et al., 1997). 
 
Several but not all studies have reported an association between CMV antibody status and 
schizophrenia and bipolar disorder (BD). Elevated levels of CMV antibodies in cerebrospinal fluid 
of patients with schizophrenia and BD have been observed (Albrecht et al., 1980; Rimon et al., 
1986; Torrey et al., 1982). More specifically, CMV may be associated with cognitive deficits in 
schizophrenia, while such an association is not present in healthy young adults. Shirts et al. 
reported an association between CMV and Trail Making Test performance in patients with 
schizophrenia (Shirts et al., 2008). Dickerson et al. reported an association between CMV 
seropositivity and deficit schizophrenia (Dickerson et al., 2006a). Deficit schizophrenia is a putative 
schizophrenia subtype characterized by primary and enduring negative symptoms. Patients 
suffering from deficit schizophrenia have poor cognitive performance (Cascella et al., 2008) and 
hippocampal dysfunction (Mucci et al., 2007). Interestingly, in healthy elderly subjects, CMV titers 
were associated with cognitive decline (episodic memory) in a prospective study (Aiello et al., 
2006).  
Most studies have focused solely on CMV seropositivity as a measure of previous exposure 
(Dickerson et al., 2006a; Shirts et al., 2008; Watson et al., 2012). But one research group has 
demonstrated a dose-response relationship between CMV serointensity (titer) and cognition 
(Aiello et al., 2006). It has been suggested that this association between CMV latent infection and 
decreased cognitive performance may be mediated by chronic inflammatory response and 
subsequent decreased hippocampal volume (Almanzar et al., 2005).  
 
Decreased hippocampal volume is consistently described in schizophrenia (Adriano et al., 2012). In 
BD, hippocampal volume is usually reported normal, but decreased only in the most severe forms 
of BD (Strasser et al., 2005). Postmortem, spectroscopy and neuropsychological studies also add 
evidence for alterations in hippocampal structure and function in BD (Frey et al., 2007). 
Declarative memory impairment is also common in euthymic BD (Bora et al., 2009). 
 
Considering the association of CMV with cognitive deficits in schizophrenia and BD, its gray matter, 
limbic and temporal affinity, and the known hippocampal dysfunctions in BD and schizophrenia, 
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 Abbreviations : CMV : cytomegalovirus ; BD : bipolar disorder ; HC: healthy controls; CVLT: California Verbal 
Learning Test; CVLT-RC-A: CVLT Recall score for list A; PANSS: Positive and Negative Syndrome Scale; YMRS: 
Young Mania Rating Scale; MADRS: Montgomery-Asberg Depression Scale 
we hypothesized that CMV seropositivity and/or antibody levels would be associated with altered 
hippocampal volume and function, as measured by a verbal memory test in patients. The CVLT 
(California Verbal Learning Test) is a widely used test of episodic verbal memory in psychiatric 
populations and is strongly but not exclusively, related to hippocampal functioning (Alexander et 
al., 2003; Chepenik et al., 2012; van Erp et al., 2008). We included two groups of patients, 
schizophrenia and BD, as elevated rates of CMV antibodies do not seem specific to schizophrenia 
but are also present in patients with BD (Tedla et al., 2011; Torrey et al., 1982).  
 
 
2. METHODS 
 
2.1 Participants 
We included 102 healthy controls (HC), 69 patients with schizophrenia and 118 patients with BD 
who underwent the clinical, cognitive and serological assessment (“CVLT sample”) (California 
Verbal Learning Test) (table 1). Among them, 52 HC, 27 patients with schizophrenia and 31 
patients with BD additionally underwent an MRI scanning (“MRI sample”) (table 2). Patients were 
recruited from two psychiatry departments of university-affiliated hospitals (Créteil and Paris, 
France). HC were recruited through advertisements. They differed from the “MRI sample” in the 
sex ratio and from the “CVLT sample” in age, sex ratio and level of education (table 1 and 2). 
 
Inclusion criteria for study participation were age between 18 and 65, no history of alcohol or drug 
abuse/dependence, no history of mental retardation, no previous head trauma with loss of 
consciousness, and no current or past cardiac or neurological disease. We excluded subjects with 
any significant cerebral anatomic anomaly. 
In addition, HC were free of any personal past or present personal psychiatric disorder and first-
degree family history of schizophrenia, schizoaffective disorder or BD. Participants were not 
included for MRI if MRI was contraindicated or if pregnant. The study was approved by the local 
IRB (Henri Mondor Hospital, Créteil, France). After complete description of the study to the 
subjects, written informed consent was obtained.  
 
2.2 Clinical and cognitive assessment 
DSM-IV personal and familial diagnoses were assessed using the Diagnostic Interview for Genetic 
Study (DIGS) and the Family Interview for Genetic Study (FIGS) (Elizabeth, 1992; Nurnberger et al., 
1994). All patients had a state evaluation of their symptoms with PANSS, YMRS and MADRS (Kay et 
al., 1987; Montgomery and Asberg, 1979; Young et al., 1978). The verbal memory evaluation 
consisted of a California Verbal Learning Test (Delis et al., 1988). We calculated the CVLT Recall for 
list A (number of total correct answers in list A; CVLT-RC-A) and CVLT-Recognition scores 
(recognition hits). We chose 1/ a total learning score as both short and long delayed recall tests 
but also total learning scores have been proven associated with hippocampus (Tischler et al., 
2006; van Norden et al., 2012; Ystad et al., 2010)  2/ CVLT-Recognition score as neuroimaging 
evidence indicates that hippocampus is crucial for achieving recognition memory tasks (Heun et 
al., 2006; Reed and Squire, 1997; Wais et al., 2006).  
 
2.3 MRI procedure 
All images were acquired on the same Siemens 3T Tim Trio MRI system, equipped with a standard 
12-channel head coil) at NeuroSpin (Saclay, France). T1 data were obtained using a 3DT1-weighted 
sequence (voxel size = 1 × 1 mm, slice thickness = 1.1 mm, TR = 2300 ms, TE = 2.98 ms, FOV = 256 
mm, nex = 1, 160 slices, flip angle=9°).  
 
2.4 MRI analysis: T1 data processing 
We applied the algorithm FMRIB's Integrated Registration and Segmentation Tool (FIRST) to 
segment the hippocampi and separately estimate volumes of left and right hippocampus. FIRST is 
part of FMRIB's Software Library (FSL 4.1.9; http://www.fmrib.ox.ac.uk/fsl) and semi-automatically 
performs both registration and segmentation of the mentioned subcortical regions (Patenaude et 
al., 2011). During registration, the input data (3D T1 images) are transformed to the Montreal 
Neurological Institute (MNI) 152 standard space, by means of affine transformations based on 12 
degrees of freedom. A sub-cortical mask is applied, to exclude voxels outside the subcortical 
regions. This step is followed by segmentation based on shape models and voxel intensities 
obtained from manually segmented images from the Center for Morphometric Analysis, 
Massachusetts General Hospital (Boston, MA, USA). Absolute volumes of subcortical structures are 
calculated, taking into account the transformations made in the first stage (Patenaude et al., 
2011). Finally a boundary correction is used to determine which boundary voxels belong to the 
structure or not, based on a statistical probability.  
As recommended by the authors of FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/first/UserGuide), we 
checked all the registrations (on axial, coronal and sagittal views); all segmented subcortical 
regions were visually checked for gross segmentation errors. No misregistration or gross 
segmentation errors were found. During this procedure, the authors were blind for the diagnoses. 
We used this FSL automated segmentation as it has been recently compared with manual 
segmentation that is currently the gold standard. FSL proved reliable for segmenting hippocampi, 
with intraclass correlation coefficients > 0.66, and small difference between mean volumes, both 
in controls and patients suffering from mood or anxiety disorders (Nugent et al., 2012). 
Additionally, we computed total intracranial volumes obtained by the sum of gray matter, white 
matter and CSF on the segmented images. Segmentation into those compartments was performed 
with SPM8 “New Segment” Module (Wellcome Department of Cognitive Neurology, London, UK) 
running on Matlab R2011 (MathWorks, Natick, USA). 
 
 
2.5 Biological measurements 
Blood was obtained by forearm vein and drawn in EDTA containing tubes. The samples were 
centrifuged for 10 min at 4 °C and the resulting plasma aliquoted into Eppendorf tubes, which 
were frozen immediately at −80 °C.  
We employed solid phase immunoassay techniques to measure IgG class antibodies to human 
CMV in the sera of the study individuals. Details have been previously described (Dickerson et al., 
2003). Briefly, the assays were performed by the reaction of diluted aliquots of sera to specific 
CMV antigens immobilized onto a solid phase surface, with the subsequent quantitation of IgG 
antibodies by reaction of bound antibodies with enzyme labeled anti-human IgG and enzyme 
substrate. The optical density of the ensuing enzyme-substrate reaction was quantified by means 
of spectrophotometric instrumentation. The assays for antibodies to CMV employed antigens 
derived from virion proteins. Reagents for these assays were obtained from IBL Laboratories, 
Hamburg Germany. Following the performance of the immunoassay procedures, a ratio was 
calculated for each sample by dividing the optical density of each sample by that of the mean 
optical density values of standard sera with defined levels of reactivity. The presence of antibodies 
to CMV was defined for each participant's sample by the measurement of a ratio greater than a 
predetermined cut-off level of 1.15. An individual with serum antibodies detected by these 
methods was defined as having serologic evidence of exposure to that infectious agent.  
 
2.6 Statistical analysis 
We performed linear regressions between CMV IgG titers and hippocampal volumes. We also 
computed linear regressions between CMV IgG titers and CVLT scores. Age, sex, number of years 
of education (final grade/graduation reached as a marker of premorbid socio-economic status) 
were entered as covariates, as they are known to influence brain structure, hippocampal function 
and CMV seropositivity (Staras et al., 2006). Present symptom scores (PANSS for patients with 
schizophrenia, MADRS and YMRS for patients with BD) were additionally used as covariates for 
CVLT analyses. When significant associations were identified, we repeated the regressions in a 
secondary analysis with total intracranial volume as an additional covariate. Normality of the 
residues was checked with QQ plots. We performed t-tests to compare demographics and CMV 
titers between groups (controls and patients).  
We used R statistical package version 2.13.1 for these analyses 
 
 
 
3. RESULTS 
 
3.1 Demographics and clinical characteristics 
 
The socio-demographic and clinical characteristics of the subjects are presented in Tables 1 and 2.  
In the “MRI sample”, the groups were similar for age, handedness and years of education. They 
differed for sex, with more women in the HC group than in the patient groups. Comparison of CMV 
antibody titers between patients and HC revealed no statistically significant difference.  
In the “CVLT sample”, patients with schizophrenia had a lower number of years of education and 
lower CMV antibody titers than HC. Patients had a lower mean CVLT score than controls. There 
was no significant correlation between CMV antibody titers and the PANSS total score (p>0.1). 
 
 
3.2 Hippocampal Volumes and CMV antibodies 
 
Within the patients with schizophrenia group, we found a significant negative correlation between 
CMV IgG antibody titer and right hippocampal volume, with a slope (non standardized beta) of 115 
mm3 per unit of CMV antibody titer (p=0.037; t= -2.24; see Fig.1). When we compared the groups 
of seropositive and seronegative patients, the difference was also significant, with CMV positive 
patients having a mean decrease of 247 mm3 in the volume of the right hippocampus as 
compared to the CMV negative group (p=0.01; t=-2.8).  
 
Within the patients with BD, a similar significant negative correlation between CMV IgG antibody 
titer and right hippocampal volume (non standardized beta of 79 mm3 per unit of CMV antibody 
titer; p=0.044; t=-2.1; see Fig.1). When we compared the groups of seropositive and seronegative 
patients, the difference was also significant, with CMV positive patients having a mean decrease of 
256 mm3 in the volume of the right hippocampus as compared to the CMV negative patients 
(p=0.044; t=-2.1). 
 
These associations remained significant after adding total intracranial volume as a covariate. 
Duration of the disease was not significantly associated with hippocampal volume, neither in 
patients with schizophrenia nor in patients with BD. 
 
In patients, no such significant associations were found between the left hippocampal volume and 
CMV antibody titers.  
No correlations were found between hippocampal volumes and CMV antibody titers in the 
controls group. 
 
 
3.3 Verbal Episodic Memory (CVLT) and CMV antibodies 
 
In the larger sample of 102 HC, 69 patients with schizophrenia and 118 patients with BD who 
underwent the clinical, cognitive and serological assessment (“CVLT sample”), we performed the 
CVLT and the CMV antibody assays. 
We found a significant negative correlation between the CVLT recognition score and the CMV 
antibody titers in the schizophrenia group (p=0.01; t=-2.6). This difference was also significant 
when considering CMV IgG as a dichotomous variable (p= 0.015; t=-2.5). A trend toward a negative 
correlation between the CVLT-RC-A and the CMV IgG level was found (p=0.06; t=-1.9).  
 
No such association was found  in the patients with BD or in the control group. 
 
 
4. DISCUSSION 
 
In patients with BD or schizophrenia, we found a negative association between CMV seropositivity, 
serointensity and right hippocampal volume. High CMV serointensity was also correlated with low 
episodic verbal memory measured with the CVLT scores in patients with schizophrenia. These 
results were obtained after adjustment for age, sex and education and were not present in HC.  
 
To our knowledge, we are the first to report an association between CMV antibody titers andh 
decreased hippocampal volume or episodic verbal memory dysfunction in patients with BD or 
schizophrenia.  
CVLT is widely used as a probe of hippocampal function, including in patients with schizophrenia 
or BD (Chepenik et al., 2012; van Erp et al., 2008). We chose to focus on two CVLT scores only: 
total learning score and recognition. We used this approach in order to decrease the number of 
tests to be performed. In addition, all CVLT scores, including learning total score, have been 
reported to be highly correlated (Ystad et al., 2010). 
To date, latent CMV infection is largely considered to be asymptomatic and non-pathogenic. 
Indeed, in our study, within the control group, we found no association of CMV antibody titers 
with hippocampal dysfunction or volume change. Nevertheless, a few studies suggest that this 
may be different in populations liable to brain damage. In a prospective study of healthy elderly 
subjects, initial CMV titers were associated with a decline in episodic memory (Aiello et al., 2006). 
The few existing previous studies in schizophrenia show heterogeneous results about the impact 
of CMV on cognitive function. Shirts and colleagues reported an association of CMV seropositivity 
with impaired cognitive function in schizophrenia (measured by the Trail Making Test, a composite 
measure of visual search, working memory, and psychomotor speed) (Shirts et al., 2008). A very 
recent study found an association between CMV seropositivity and a composite heritable measure 
of cognitive performance in patients with schizophrenia (Watson et al., 2012). Two other large 
studies failed to find an association between CMV seropositivity and measures of global cognitive 
functioning in schizophrenia (Dickerson et al., 2003; Yolken et al., 2011), maybe because the tests 
used were less sensitive to deficits in verbal memory tests.  
 
Similar to our result, two studies found that another herpesvirus, HSV (Herpes Simplex Virus), is 
related to cognitive (executive) deficits and gray matter decreases in patients with schizophrenia 
but not in controls (Prasad et al., 2010; Prasad et al., 2012b; Schretlen et al., 2010). HSV-1 is also 
associated with cognitive deficits in patients with BD but not (or at a far lesser extent) in HC (Aiello 
et al., 2006; Dickerson et al., 2004; Dickerson et al., 2006b; Gerber et al., 2012). 
Therefore, some authors have proposed that patients with schizophrenia and patients with BD 
displayean increased brain susceptibility/liability to exogenous assaults (Schretlen et al., 2010). 
Infectious assaults such as CMV or HSV do not cause schizophrenia or BD per se. Rather, 
schizophrenia and BD may render brains liable to CMV- or HSV-damaging effects that would not 
be present in HC. Our results support this hypothesis. 
 
 
Several putative mechanisms may account for this association between CMV serointensity and 
hippocampal decreased volume and altered function. 
 
First, one can assume a direct effect of CMV on early neurodevelopment. Our finding of a 
decreased hippocampal volume associated with CMV antibody titers is consistent with the 
hippocampal tropism of CMV observed in animal models, especially in the latent phase of 
infection (Arai et al., 2003; Shinmura et al., 1997; Tsutsui et al., 2005). Herpesviruses display a 
common temporal and particularly hippocampal tropism with hippocampal dysfunction. In HSV 
encephalitis, hippocampal volume reduction is frequent and memory impairment is a cardinal 
symptom (Geuze et al., 2005). Intranasal inoculation of mice with HSV-1 resulted in the spread of 
HSV-1 to the hippocampus, amygdala, midbrain and brainstem via the olfactory bulb (Barnett et 
al., 1993). Epstein-Barr-Virus infections have also been reported to point to hippocampal damage 
(Hausler et al., 2002; Kremer et al., 2010). Recent studies highlighted the possible role of HHV-6 in 
mesial temporal lobe epilepsy with detection of HHV-6 DNA in medial temporal areas 
(Fotheringham et al., 2007; Niehusmann et al., 2010). 
But we think this effect is unlikely in our population. We cannot define the date exposure to CMV 
in the patients in our sample. But the live birth prevalence of congenital CMV infection in the 
developed world is below 1% (Kenneson and Cannon, 2007). In addition, the prevalence of 
congenital CMV is below 2% all over the world (Gaytant et al., 2002). Epidemiological studies 
report that the prevalence of CMV antibodies increases with age ranging from 36% in 6-11 years-
old children to 90% in those aged >80 years in the US (Staras et al., 2006). These data and other 
suggest that CMV seroprevalence increases with age throughout the lifespan. Therefore, it seems 
unlikely that CMV exerts effects on the hippocampus though interference with early 
neurodevelopment.  
 
A more probable explanation is that the association is related to the immune response to infection 
by CMV.  A general dysregulation of immune response has been observed both in schizophrenia 
and BD. In schizophrenia, HLA polymorphisms are among the strongest associated loci with 
liability to disease (Shi et al., 2009; Stefansson et al., 2009). Higher levels of pro-inflammatory 
cytokines have been frequently reported and anti-inflammatory medications are being assessed in 
schizophrenia (Mansur et al., 2012). The presence of chronic hippocampal inflammation of 
schizophrenia has been suggested by a PET study (Doorduin et al., 2009). Similarly, in BD, pro-
inflammatory processes have been observed, such as elevated levels of cytokines, especially Il-6. 
Significant associations have been reported between BD and HLA polymorphisms (Hamdani et al., 
2012; Purcell et al., 2009). The chronic systemic inflammation in BD and schizophrenia is a possible 
trigger for lower hippocampal volumes and poorer cognitive performance (Marsland et al., 2008; 
Marsland et al., 2006; Mondelli et al., 2010). 
In patients, chronic infection with CMV would induce an abnormally elevated production of 
proinflammatory cytokines that would cause hippocampal damage (Lokensgard et al., 2002). In 
this model, the latent CMV infection would trigger a chronic immune response, possibly during its 
reactivations. A reflect of this activation would be the higher levels of CMV antibodies. The 
deregulation of immune response in BD and schizophrenia may account for a higher impact of 
CMV latent infection on brain tissue in patients relative to controls.  
 
Lastly, we cannot exclude a direct neurotoxic effect of CMV on adult neurons, especially during 
reactivations. Animal models of CMV infection do not support this hypothesis (Shinmura et al., 
1997; Tsutsui et al., 2005). An alternative explanation may be a dysregulation of neurotransmitter 
signaling due to CMV: some authors have reported that CMV infection inhibits the expression of 
NMDA receptors in primary neuronal cultures and in the developing mice hippocampus (Kosugi et 
al., 2005). This disturbance of NMDA signaling linked to CMV may be related to functional 
alteration of hippocampal function. 
 
The association of higher CMV antibodies titers with smaller hippocampal volume was right-sided. 
Interestingly, in a prospective study of patients with first-episode psychosis (affective disorder or 
schizophrenia), baseline right hippocampal volume has been associated with poor outcome at 
follow-up (de Castro-Manglano et al., 2011).  
 
 
Limitations  
The association between CMV serointensity and verbal memory performance was only present in 
patients with schizophrenia. This suggests that the association of CMV antibody titers with 
damage to hippocampal function may be related to different mechanisms in patients with 
schizophrenia and BD. This finding needs to be confirmed in larger samples of both populations, 
including patients with BD with and without psychotic features.  
Secondly, we did not correct for multiple comparisons. Nevertheless, the similar associations in 
different groups of patients (schizophrenia and BD) along with the convergence of data for 
hippocampal size and function strongly support our results. This limitation should be addressed in 
a future study with larger statistical power to perform correction for multiple comparisons.  
Thirdly, our study was cross sectional by nature. This limits the degree to which causal inferences 
can be made. In particular, there is evidence that lithium, antipsychotics and antidepressants have 
an effect on hippocampal volumes (Ebdrup et al., 2011; Moore et al., 2000). The cross sectional 
design and the multiple (current and past) medication classes taken by the patients, preclude our 
analyzing these medication effects. Future longitudinal studies may help solve this issue. 
Fourthly, we used number of years of education as a proxy for premorbid socioeconomic status. 
This variable may have been impacted by the onset of the disease. Such an impact, if existent, 
would be rather small in our study as patients have a mean number of years of education very 
similar to that of the controls, at least for the “MRI sample”. Socioeconomic status is 
conventionally indicated by the number of years of individual education and occupation (Watson 
et al., 2012). Occupation is likely to be confounded by the illness status and severity. 
Fifthly, raw CMV IgG levels were higher in patients than in controls in the larger sample (“CVLT 
sample”). Such a result is also present in very recent reports (Watson et al., 2012). This may be 
linked to several factors but does not modify our conclusions since our main analyses were intra-
group correlations. Furthermore, most of the existing studies do not found any association 
between CMV levels and schizophrenia or BD per se, but with subforms of these diseases (e.g. 
deficit schizophrenia). This is another argument for a further exploration of CMV in subgroups of 
patients. 
Lastly, we only explored the hippocampal region, as it is a preferential site of infection for CMV 
and is also crucial for episodic memory processes. However, episodic memory is also dependent 
on other brain regions such as the right dorsolateral prefrontal cortex (Henson et al., 1999; 
Johnson et al., 2001; Sowell et al., 2001). We chose to focus on hippocampi as their volumes have 
been shown to be the best predictor of recall and recognition discriminability (Kramer et al., 
2005). Nevertheless, future, larger studies should explore this issue. 
 
5. Conclusion and perspectives 
In our sample, high CMV IgG titers are associated with both decreased hippocampal volume and 
poorer episodic verbal memory in patients with schizophrenia or BD. This is the first study to 
report such an association. The mechanism of the association between CMV antibody titers and 
hippocampal volume and function warrants further exploration and, if confirmed, may generate 
novel prophylactic and therapeutic approaches as with other herpesviruses. A recent randomized 
double-blind placebo-controlled trial using valacyclovir as an add-on to antipsychotics has shown 
the efficacy of valacyclovir to reduce impairments on some cognitive tasks (Prasad et al., 2012a). If 
an immune mechanism is confirmed, trials involving anti-inflammatory and cytokine blocking 
agents may also be considered. Finally, several CMV vaccines are currently under development for 
immunocompromised individuals (transplant patients, HIV, fetus). Some of these vaccines are 
already under phase I and phase II clinical trials. But there is no clear prospect of an efficient 
vaccine in the near future (Schleiss, 2008). In sum, our study opens new potential mechanistic, 
prophylactic and therapeutic avenues for cognitive deficits in schizophrenia and BD. 
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Figure 1 
Right hippocampal volumes and levels of antiCMV IgG in the schizophrenia group 
 
Figure 2 
Right hippocampal volumes and levels of antiCMV IgG in the bipolar disorder group 
 
 
 
 
 
 
  
     
 
Table 1: sociodemographic and clinical characteristics of the “CVLT sample” 
Mean (SD) Healthy controls Patients with BD Patients with 
schizophrenia 
p-value 
N 102 118 69  
Age 37.8 (13.9) 45.3 (12.6) 39.4 (13.1) p<0.05 
N males 65 59 50 p<0.05 
Years of 
education 
12.4 (2.6) 13.0 (2.6) 10.9 (2.5) p<0.05 
CMV IgG (optical 
density ratio) 
2.98 (2.0) 2.63 (2.0) 2.24 (1.7) p<0.05 
Age at onset  26.3 (10.2) 23.9 (6.8) NS 
PANSS   68.0 (27.3)  
MADRS  7.0 (9.3)   
YMRS  3.8 (5.4)   
CVLT Recall for 
List A 
54.0 (8.3) 47.4 (11.4) 38.1 (11.5) p<0.05 
CVLT Recognition 
Score 
14.8 (1.8) 13.9 (2.4) 13.4 (2.4) p<0.05 
 
 
Table 2: sociodemographic and clinical characteristics of the “MRI sample” 
mean (SD) 
Healthy 
controls 
Patients with 
BD Patients with schizophrenia p-value 
N   52 31 27  
Age 36.6 (11.8) 38.2 (12.5) 31.4 (9.9) NS 
N males 21 21 7 p<0.05 
N left handed 2 2 2 NS 
Years of education 12.3 (2.9) 13.1 (2.4) 11.8 (2.9) NS 
CMV IgG (optical 
density ratio) 2.7 (2.0) 2.5 (1.9) 2.7 (1.7) NS 
Right hippocampal 
volume (mm3) 
Left Hippocampal 
Volume (mm3) 
Age at onset 
3880 (475) 
 
3913 (397) 
 
 
4026 (370) 
 
3907 (403) 
 
23.0 (8.4) 
3786 (506) 
 
3746 (509) 
 
22.7 (4.6) 
NS 
 
NS 
 
NS 
PANSS   71.6 (20.6)  
MADRS  6.2 (7.0)   
YMRS  3.9 (5.9)   
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